about
HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathwayHuman interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivoHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells.The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyHIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesTreatment of Kaposi's sarcoma--an update.HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialInterferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo.Antitumour effects of antiretroviral therapy.Infection of human endothelial cells with Epstein-Barr virus.HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialPharmacological management of Kaposi's sarcoma.Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.Epstein-Barr virus as an agent of haematological disease.HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.High serum IL-2 levels are predictive of prolonged survival in multiple myeloma.The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells.Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a.A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.HIV protease inhibitors as new treatment options for Kaposi's sarcoma.Regression of experimental human leukemias and solid tumors induced by Epstein-Barr virus-immortalized B cells.Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir."cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells.The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia‐Associated Aggressive Classic Kaposi’s Sarcoma during Interferon‐α Therapy: A Case ReportIdentification of the hemangioblast in postnatal lifeInterleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinomaP-451 HIV-protease inhibitors as antitumoral therapy in advanced NSCLC patientsSerum Concentrations of Fibroblast Growth Factor 2 Are Increased in HIV Type 1-Infected Patients and Inversely Related to Survival ProbabilityInterleukin-15 Promotes Angiogenesisin VivoA Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12HIGH SERUM INTERLEUKIN-2 LEVELS IN ACUTE MYELOID LEUKAEMIA (AML) ARE ASSOCIATED WITH FAB M4 AND M5 SUBTYPESAnti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease
P50
Q24541552-63672238-1F63-4737-86B3-A35D2EDFA285Q24678892-3E467242-AD70-4EFC-B504-EB3574D527D9Q30381447-77E88E02-0068-475F-92DC-ADBFB8403F3AQ33684710-BBA64049-B01C-45D6-A2CD-66E991FD80E2Q33864926-C7AF8359-A641-4C6E-ACC8-81BD38E927E0Q34477471-80E65262-5E5A-4414-BA08-F3AD92C0CCCCQ35002125-2C74A3E3-C868-47E5-99CE-496880A2A5D9Q35058310-DB1A2363-0F40-4352-9C2E-5F6C72C66261Q35215799-2CF05A30-FE7F-45DA-86DD-DFB5AA290874Q35294664-2DBD9D3A-49A6-4CCC-BA0A-AEF3E8AED20CQ35552889-142BC0AA-F230-43A4-B890-8FBC2EF5D761Q35931062-9C396836-1791-453A-BB83-2A617A112F15Q35934144-353A6EF3-B2E9-4D27-8C24-25838D5C6380Q36365385-613AE125-DD18-428B-B96E-FC66023FE591Q36986644-E403F01E-CA0E-4ED8-BA09-3EE2033DF181Q37868566-DB6508E0-48EA-475E-AE6B-9BF0E848C1F6Q38533881-826B9BC4-7647-4A3B-9908-46FCC2321158Q39682383-D552B947-E1A5-4E72-BB03-C52FD2EC6678Q40475844-083D0F60-15AC-4BE0-B6A3-7FF553110238Q40747284-AE7D1BE7-4D95-4B5E-98CA-01693FAD5804Q41977460-F086BD58-AC6B-49CE-8096-08AFFB420D9EQ42225690-860CE1D3-9945-4814-95F8-88C5AFB17DBFQ42447415-FD6C1B09-B5CE-4238-B152-ED78FA0E223DQ44499582-6C7137E9-351F-44FD-92A6-439EC550FD69Q44577471-FC951BE1-A118-4D06-A003-91F7416AE648Q45772589-40FA1240-6C0E-4E73-8E38-5CDC8096A827Q46147545-6B8D67D3-D5C5-4013-96A2-9F5777771AE3Q46698274-072AA57E-E4F4-437D-8C30-10424334E8FEQ47961302-46D5D1F4-402F-4998-9D6A-4D946E1A4599Q54215275-F5CB3A75-B053-450F-81C8-76C007EC5A5BQ59284073-27B9BBA4-B184-45BB-BABC-116091F44FF4Q59592052-59A58E82-DB92-4351-8A3F-F479CCCCD4D0Q59647821-59F83284-C124-4F2D-A808-DBEE22EC6F88Q59647823-E258FAB2-FFEB-4566-879A-0D05ECE33EDCQ60194030-D15C0D6F-39BA-4862-9D42-22C26CA6BFA7Q60194035-737BDCFB-2037-4DEA-A190-657A2CAFB243Q60194037-1BC2C035-3585-4C0B-A5D9-17069BFBB672Q60194045-9AB364E8-F0D5-4A9B-A765-916D79D79470Q92906228-60FDF0C9-5098-4DBE-AF2B-D4018DF7F9C7
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cecilia Sgadari
@ast
Cecilia Sgadari
@en
Cecilia Sgadari
@es
Cecilia Sgadari
@nl
Cecilia Sgadari
@sl
type
label
Cecilia Sgadari
@ast
Cecilia Sgadari
@en
Cecilia Sgadari
@es
Cecilia Sgadari
@nl
Cecilia Sgadari
@sl
prefLabel
Cecilia Sgadari
@ast
Cecilia Sgadari
@en
Cecilia Sgadari
@es
Cecilia Sgadari
@nl
Cecilia Sgadari
@sl
P1053
H-4302-2016
P106
P1153
57109163500
P21
P2798
P31
P3829
P496
0000-0003-0364-4912